{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-001459","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.755593+00:00","generated_at":"2026-05-16T11:04:11.363976+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rhythm Pharma Q4 2025 IMCIVREE revenue ~$57M (+11% QoQ); FY2025 ~$194M (+50% YoY)","bullets":["Q4 2025 net product revenue ~$57M, up 11% sequentially from Q3 2025.","FY2025 net product revenue ~$194M, a ~50% increase from $130M in FY2024.","U.S. sales contributed ~68% of Q4 and ~69% of full-year 2025 revenues.","FDA PDUFA goal date of March 20, 2026 for setmelanotide sNDA in acquired hypothalamic obesity.","Topline data from Phase 3 EMANATE trial in MC4R pathway diseases expected in Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-001459","json":"https://secwatch.observer/filing/0001628280-26-001459.json","markdown":"https://secwatch.observer/filing/0001628280-26-001459.md","text":"https://secwatch.observer/filing/0001628280-26-001459.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000162828026001459/0001628280-26-001459-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000162828026001459/rytm-20260109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:04:11.363976+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}